—To evaluate the effect of a standard dose of injected recombinant growth hormone on the integrated concentrations of growth hormone and insulin.
—Integrated concentrations were studied in patients receiving growth hormone therapy before and on the day of injection.
—Pediatric endocrine clinic and diagnostic unit.
—Twelve growth hormone—deficient patients with poor linear growth and deficient growth hormone response to provocative stimulation and/or 24-hour integrated concentration.
—Patients received subcutaneous injections of 0.06 mg/kg of growth hormone three times a week in the evenings at approximately 8 pm. Integrated concentrations were measured again approximately 6 months after the start of therapy at the time of a growth hormone injection.
Measurements and Results.
—Mean growth hormone dose administered was 2.0±0.5 mg. Integrated concentration of growth hormone was 2.2±0.9 μg/L before therapy. The integrated concentration of growth hormone after treatment (14.6±4.2 μg/L) was significantly higher than that before treatment and that of normally growing children (P<.001). After injection, peak growth hormone level was 53.7±24.1 μg/L; time to peak growth hormone level, 4.8±1.2 hours; constant of elimination, 0.24±0.06 per hour; half life, 3.0±0.7 hours; area under the curve, 328±85 (μg·h)L; clearance rate, 107.6±34.3 mL/min (3.2±0.8 mL/min per kilogram based on weight, 95.2±24.2 mL/min per meter squared based on surface area). There was no relationship between integrated concentration of growth hormone or pharmacokinetic variables after treatment and the growth response to 6 months' therapy. Integrated concentration of insulin before treatment was 19.0±10.9 mU/L, which was significantly lower than that after injection of growth hormone (33.4±9.5 mU/L; n=9, P<.0008).
—Integrated concentrations of growth hormone after an injection of 0.06 mg/kg of growth hormone are considerably higher than spontaneous integrated concentrations of growth hormone observed in normally growing children, and associated with a rise in insulin secretion. These changes may be pertinent in patients with underlying insulin resistance or when higher doses of growth hormone are used for therapy.(AJDC. 1993;147:274-278)
Chalew SA, Phillip M, Kowarski AA. Plasma Integrated Concentration of Growth Hormone After Recombinant Human Growth Hormone Injection: Implications for Determining an Optimal Dose. Am J Dis Child. 1993;147(3):274–278. doi:10.1001/archpedi.1993.02160270036014
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.